Gangliosides
Research stageRecent clinical, regulatory, research and industry developments relating to this drug.
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes6
Journals, researchers & institutions
- Blood1
- International journal of molecular sciences1
- The New England journal of medicine1
- Anderson B1
- Brenner MK1
- Buxton A1
- Chen HX1
- Cohn SL1
- Diouf O1
- Dotti G1
- Gee AP1
- Center for Cell and Gene Therapy1
- General Hospital "Ivo Pedišić"1
- Laboratory for Molecular Neurobiology and Neurochemistry1
- School of Medicine1
- University of California1
- University Psychiatric Hospital Vrapče1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as Gangliosides in the shared literature.
Studied across the same disease area as Gangliosides in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature